Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New AI tool could spot dangerous liver cancer invasion without a biopsy

NCT ID NCT07170345

Diagnosis Sponsor: Chinese Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing an artificial intelligence system that analyzes CT scans to predict microvascular invasion (MVI) in liver cancer patients. MVI is a key sign of aggressive cancer that currently can only be confirmed after surgery. The AI tool aims to give doctors this information beforehand, helping them plan better surgeries and treatments. The trial will enroll 400 adults with liver cancer who are scheduled for surgery, comparing the AI's predictions to standard lab results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence-based computer-aided diagnosis (CAD) system
What this could lead to
If successful, this could provide doctors with a reliable, non-invasive tool to predict microvascular invasion before surgery, helping tailor treatment and potentially improve survival for liver cancer patients.
What could go wrong
This is an early-stage observational study, and the AI system may not perform accurately across different hospitals or patient groups. It is not yet proven to improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥18 years) with hepatocellular carcinoma who undergo curative-intent surgical treatment, including hepatic resection or liver transplantation, at participating clinical centers. Approximately 5,000 retrospective cases and 400 prospective cases will be included. All participants will have preoperative multiphase CT imaging and postoperative pathological evaluation with documented microvascular invasion (MVI) status.

Ages

18 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Confirmed diagnosis of hepatocellular carcinoma (HCC) according to the Chinese Clinical Practice Guidelines for Primary Liver Cancer. * Eligible for surgical intervention (hepatic resection or liver transplantation) according to the Chinese Clinical Practice Guidelines for Cancer, including stages Ia, Ib, and IIa. * Preoperative imaging examination performed within 1 month before surgery. * Availability of histopathological evaluation with documented microvascular invasion (MVI) status. Exclusion Criteria: * History of prior antitumor treatment, including preoperative surgical intervention, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), systemic therapy, or any other preoperative intervention. * Presence of major vascular invasion, bile duct invasion/thrombosis, extrahepatic metastasis, or lymph node involvement. * Diffuse hepatocellular carcinoma or tumor rupture with hemorrhage. * Lack of key data required for primary analysis. * Poor image quality that prevents reliable qualitative or radiomics analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC) Microvascular invasion (MVI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tsinghua Changgeng Hospital

    RECRUITING

    Beijing, China

  • Beijing YouAn Hospital

    RECRUITING

    Beijing, China

  • Dazhou Central Hospital

    RECRUITING

    Dazhou, Sichuan, China

  • Eastern Hepatobiliary Surgery Hospital

    RECRUITING

    Shanghai, China

  • Fifth Affiliated Hospital, Sun Yat-Sen University

    RECRUITING

    Zhuhai, Guangdong, China

  • First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, China

  • First Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, China

  • First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, China

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, China

  • Guizhou Provincial People's Hospital

    RECRUITING

    Guiyang, Guizhou, China

  • Henan Provincial People's Hospital

    RECRUITING

    Zhengzhou, Henan, China

  • Meng Chao Hepatobiliary Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, China

  • Shengjing Hospital

    RECRUITING

    Shenyang, Liaoning, China

  • The First People's Hospital of Yunnan Province

    RECRUITING

    Kunming, Yunnan, China

  • West China Hospital

    RECRUITING

    Chengdu, Sichuan, China

  • Yunnan Cancer Hospital

    RECRUITING

    Kunming, Yunnan, China

  • Zhuhai People's Hospital

    RECRUITING

    Zhuhai, Guangdong, China

  • Zhujiang Hospital

    RECRUITING

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.